Beacon presents clinical data update

Syncona Limited

19 September 2024

 

19 September 2024

Syncona Limited

Beacon presents 36-month clinical data from Phase I/II trial in XLRP

Syncona Ltd, (the "Company"), a leading life science investor focused on creating, building and scaling global leaders in life science, today notes that its portfolio company, Beacon Therapeutics ("Beacon") presented 36-month interim safety and efficacy results from its Phase I/II HORIZON trial of its lead asset, AGTC-501, in patients with X-linked retinitis pigmentosa (XLRP). Data was presented on 19 September 2024 at the 24^th EURETINA conference in Barcelona, Spain.

Key highlights from the presentation include:

·      With safety as the primary endpoint of this trial, AGTC-501 continues to be well-tolerated with no clinically significant safety events related to the therapy reported amongst the 29 patients enrolled

·      Data also demonstrated that a difference in visual function between the treated and untreated eyes was still observed at month 36, which is the trial's secondary endpoint

·      Benefit-risk profile of AGTC-501 supports ongoing clinical development for the treatment of patients with XLRP caused by RPGR mutations.

Beacon will publish 24-month data from the Phase II SKYLINE trial in XLRP later in H2 CY2024, a potential key value inflection point for the company.

Beacon's announcement is copied below and can be accessed at the company's website at beacontx.com.

Chris Hollowood, Chief Executive Officer of Syncona Investment Management Limited, said: "This data presented by Beacon highlights the strong safety profile of this therapy, as well as promising efficacy signals and a continued durability profile out to 36 months post-dosing, which is particularly pleasing for an exploratory Phase I/II trial. We now look forward to the upcoming 24-month data read-out from the Phase II SKYLINE trial which has the benefit of an optimised dose and greater surgical repeatability. The Beacon team continue to execute well, with both the Phase II DAWN and Phase II/III registrational VISTA trials currently recruiting patients following the introduction of an improved manufacturing process."  

[ENDS]

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: [phone]

FTI Consulting

Ben Atwell / Tim Stamper

Tel: [phone] 

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP

London, UK and Cambridge, MA, September 19, 2024 - Beacon Therapeutics Holdings Limited ('Beacon' or 'the Company'), a leading ophthalmic gene therapy company with a purpose to save and restore the vision of patients with blinding retinal diseases, today presented 36-month interim results from its Phase I/2 HORIZON trial of its lead asset, AGTC-501, in patients with X-linked retinitis pigmentosa (XLRP) at the 24th EURETINA Congress held in Barcelona, Spain.

Key presentation highlights included:

·      AGTC-501 was reported to be generally safe and well-tolerated in the 29 patients enrolled with no clinically significant safety events related to the therapy.

·      Data also demonstrated that a difference in visual function between the treated and untreated eyes was still observed at month 36.

·      The benefit-risk profile of AGTC-501 supports ongoing clinical development for the treatment of patients with XLRP caused by RPGR mutations.

Lance Baldo, MD, Chief Executive Officer of Beacon, stated, "This emerging longer-term data is another clinical validation of the safety of AGTC-501 for the treatment of XLRP. We look forward to achieving several upcoming clinical milestones, including 24-month data from the Phase 2 SKYLINE trial in XLRP later this year, and continued enrollment into our open-label Phase 2 DAWN trial and Phase 2/3 VISTA trial."

HORIZON is a Phase 1/2, open-label, dose-escalation study of patients with XLRP treated with subretinal AGTC-501, which has completed enrollment of 29 male participants and all participants are in long-term follow-up.

Presentation - Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa (XLRP) Phase 1/2 Multicenter Study (HORIZON): 36-Month Interim Results

Presenter - Paul Yang, MD, PhD, Chief, Paul H. Casey Ophthalmic Genetics Division, Casey Eye Institute, OHSU

The presentation took place on Thursday, September 19^th at 15:30 CEST.

About Beacon Therapeutics

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.

The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD). Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space.

Lead development candidate AGTC-501, is a gene therapy program currently being investigated for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss, primarily in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss.

Beacon is supported by funds from Syncona Limited, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.

Find out more about Beacon Therapeutics at beacontx.com.

Contact:

[e-mail]

Media:

[e-mail]

###

 

END